P/E ratio for QuidelOrtho (QDEL)
P/E ratio as of April 2024 (TTM): 202
According to QuidelOrtho's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 201.65. At the end of 2022 the company had a P/E ratio of 6.81.
P/E ratio history for QuidelOrtho from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 6.81 | -15.25% |
| 2021 | 8.04 | -13.99% |
| 2020 | 9.34 | -77.84% |
| 2019 | 42.2 | 70.96% |
| 2018 | 24.7 | -113.08% |
| 2017 | -188 | 278.36% |
| 2016 | -49.8 | -60.05% |
| 2015 | -125 | -13.76% |
| 2014 | -145 | -202.98% |
| 2013 | 140 | 12.81% |
| 2012 | 124 | 97.44% |
| 2011 | 63.0 | -274.51% |
| 2010 | -36.1 | -390.99% |
| 2009 | 12.4 | -43.96% |
| 2008 | 22.2 | -49.94% |
| 2007 | 44.2 | 117.68% |
| 2006 | 20.3 | -154.79% |
| 2005 | -37.1 | 46.08% |
| 2004 | -25.4 | -258.01% |
| 2003 | 16.1 | -76.77% |
| 2002 | 69.2 | -91% |
| 2001 | 769 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 37.4 | -81.47% | 🇺🇸 USA |
 Becton Dickinson BDX | 41.6 | -79.35% | 🇺🇸 USA |
 Danaher DHR | 30.6 | -84.81% | 🇺🇸 USA |
 PerkinElmer
PKI | 15.0 | -92.58% | 🇺🇸 USA |
 OraSure Technologies OSUR | 9.16 | -95.46% | 🇺🇸 USA |
 Meridian Bioscience VIVO | 35.0 | -82.63% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.